Estrogen receptor beta as target for colorectal cancer prevention. Issue 1 (1st March 2016)

• Record Type: Journal Article
• Authors: Williams, Cecilia; DiLeo, Alfredo; Niv, Yaron; Gustafsson, Jan-Åke
• Is Part Of: Cancer letters. Volume 372:Issue 1(2016)
• Page Start: 48
• Page End: 56
• Publication Date: 2016-03-01
• Subjects: CRC colorectal cancer -- ER estrogen receptor -- CIMP CpG island methylator phenotype -- FAP familial adenomatous polyposis -- IBD inflammatory bowel disease -- RR relative risk -- OR odds ratios; Colorectal cancer -- Estrogen -- Estrogen receptor beta -- Phytoestrogens -- Prevention -- Gene expression; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2015.12.009
• Languages: English
• ISSNs: 0304-3835

Abstract

Highlights: Estrogen exposure decreases the risk of colorectal cancer. Experimental evidence supports activation of ERβ in prevention. ERβ regulates DNA repair and apoptosis through p53 signaling. ERβ repressed oncogenes and metastasis. Phytoestrogens activate ERβ and show therapeutic efficacy. Abstract: Colorectal cancer (CRC) is a leading cause of death in the United States. Despite its slow development and the capacity for early diagnosis, current preventive approaches are not sufficient. However, a role for estrogen has been demonstrated in multiple epidemiologic studies, which may benefit CRC prevention. A large body of evidence from preclinical studies indicates that expression of the estrogen receptor beta (ERβ/ESR2) demonstrates an inverse relationship with the presence of colorectal polyps and stage of tumors, and can mediate a protective response. Natural compounds, including phytoestrogens, or synthetic ERβ selective agonists, can activate or upregulate ERβ in the colon and promote apoptosis in preclinical models and in clinical experience. Importantly, this activity has been associated with a reduction in polyp formation and, in rodent models of CRC, has been shown to lower incidence of colon adenocarcinoma. Collectively, these findings indicate that targeted activation of ERβ may represent a novel clinical approach for management of colorectal adenomatous polyps and prevention of colorectal carcinoma in patients at risk for this condition. In this review, we discuss the potential of new chemopreventive or dietary approaches based on estrogen signaling.